Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. 4 Smaller, independent SPs are declining, representing 47% of accredited SPs in 2018, compared to 59% in 2015. Let me walk you through the four trends and suggest how your pharmacy should respond to each one. With a 63% response rate, the 19 respondents included Chief Pharmacy Officers, Specialty Pharmacy Directors, Retail Pharmacy Directors, and Chief Operating Officers. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Unique Reimbursement Models for High Investment Therapy. Diagnosis and Treatment of IBS. continued strong growth … The responding health systems have a median net patient revenue (NPR) of $4.6 billion and own or operate a total of 380 hospitals. Volume Based Purchasing – the Netflix Model. It would not address short term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments. by Denise Cabrera. Pembroke Consulting, Inc., and. Healthcare will … It is estimated that 17% of America’s personal healthcare spending is for drug therapy. THE SHIFTING LANDSCAPE ACCESS TRENDS IN SPECIALTY PHARMACY 2020-23 7 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 to 47.7% in 2019 per ESI.10 On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth, with a 10% to 0.3% dollar volume increase, per IQVIA. More than 900 investigational new drug applications have been submitted to the FDA in 2020. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy to ensure cost effective access to quality care. Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series “Specialty Market Trends and the Market Place Realities for Pharmacy Benefit Managers” Total trend could rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020. Value based arrangements and risk sharing across plan sponsors, PBMs, Payers and manufacturers is being considered in order to sustain affordability, ensure access to care and continue to incentivize manufacturer research and development efforts. Can Formulary Management Bring It Down to Earth?, Managed Care, 2019, FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, 2017, https://www.cigna.com/newsroom/news-releases/2019/pdf/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients.pdf, http://image.messageinsite.com/lib/fe5615707d600c747210/m/2/757027d4-dff0-4c1b-a50a-ce78326b9917.pdf, 5 Ways Talking to Strangers May Boost Your Emotional Intelligence, Driving Optimal Results Through Individual/Team Performance-Based Incentive Compensation Plans, The Future of Benefits Administration Technology for HR Professionals, Most Brokers Say They Have All the Answers, COVID-19 and Mid-Year Plan Amendments – Employer Compliance Checklist, 7 Steps to Take When a Star Employee Disengages, University of Memphis – Academic Training in HR Management, Is Western Governors University Accredited | Read the Latest World News - News World, The Three Top Challenges to Earning a Degree, Factors in Assessing Your Hiring Strategy - HRProfessionalsMagazine, Recruiting Tips During Times of Uncertainty, Gloria Sinclair Miller, SHRM-SCP, SHRM Field Services Representative, Dr. Kathy Tuberville Recipient of 2020 HR Professional Excellence Award, Profile: Emily M. Dickens, SHRM Corporate Secretary and Chief of Staff, Preview of SHRM-Atlanta SOAHR Conference March 25-27. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. Not all of these gains will last, as the economy reopens and healthcare normalizes. Specialty drugs are used for the treatment of complex, chronic, or rare conditions such as cancers and hepatitis C. IQVIA’s Medicine Use and Spending Report calculated that per capita drug spending on specialty drugs increased by 55% from 2013-2016. Precision medicine targets specific genes, based on the patient’s condition. Between 2020 and 2027, retail drug spending under private health plans is projected to increase at an annual rate of 3% to 6%; besides the slow growth of the US biosimilar market, the report cited new costly therapies, mainly specialty drugs, as well as a drop-off in the impact of lower-cost generics. High investment therapies have stretched current reimbursement models beyond their capacity. 2020-01-31 15:32:00. It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Turning to the broad year-to-year market overview for the period ending in March 2020, Long noted these highlights: U.S. medicines’ total market growth reached 6.7%, less than the growth of 7.4% in the retail and mail order segments. Spark Therapeutics has agreed to VBR for its gene therapy, Luxturna, which cures a retinal disease causing blindness. Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). Puts the onus on the Payer to prove failure of efficacy. The specialty pharmacy (SP) market is shifting and consolidating. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. Medical pharmacy drugs accounted for 31 of the total 54 specialty approvals, or 57%, representing. As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. Payer. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. I review: Novartis expects to treat 100 infants each quarter. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. Specialty and high-cost medications continue to dominate the news. 2019. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. Here are six developments we believe are worth watching and the ways that action today can help people and communities across the United States on their path to better health. Videos. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S ... $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in ... snapshot of specialty pharmacy mergers and acquisitions in 2016.4 To properly serve their patients, pharmacists working in the outpatient setting—whether or not Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. 1. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. Here are the top 10, Opinion: Routine testing is essential to combat Covid-19 surges, Pfizer to supply US with 100 million more doses of vaccine, The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty, Medical record indexing in the EHR era: Podcast with EDCO CEO Andrew Fehlman, ShopRite plans to distribute COVID-19 vaccine, HDA issues statement on COVID-19 emergency relief package, Amgen Receives FDA Approval for Rituximab Biosimilar Riabni, American biopharmaceutical manufacturing: Fueling economic growth now and for years to come, The Pharmacy Benefit Brief | December 2020, Vaccine Development and Approval in a Time of Pandemic, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—a... Preorder now: The 2020-21 Economic Report on Pharm... Three Ways to Boost Patient Access to Orphan Drugs... My Wall Street Journal Op-Ed about the 340B Program. Denise CabreraLicensed Clinical PharmacistNational Pharmacy Practice Leader   McGriff Employee Benefit Solutions813-682-1515Denise.Cabrera@mcgriffinsurance.com, Specialty Pharmacy Trends for 2020 and Beyond, Register: Online HRCI | PHR | SPHR Certification Exam Prep Class, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet, https://bioprocessintl.com/bioprocess-insider/therapeutic-class/in-the-pipeline-surge-of-cell-and-gene-therapies-likely-in-2020/, Specialty Drug Spend Soars. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. New pharmacogenomic tests and gene therapies are entering the market at an astounding rate and are expected to grow by 10.5% over the next five years. These high investment therapies have stretched current reimbursement models beyond their capacity. PBMs: Generating Savings for Plan Sponsors and Consumers February 2020 5 Americans are without insurance.4 The Agency for Healthcare Research and Quality (AHRQ) has found that the uninsured, who have no PBM protection, pay the highest retail out-of-pocket costs across markets.5 PBMs and their clients guide how actively pharmacy benefits are managed within the context of applicable The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vii The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above: Unique models are being considered in order to manage patient access and cost of care. A biosimilar for Tecfidera, used to treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales of $3.5M. The MMIT survey data show a leap in white bagging as of mid-2020. You can watch the full video below. SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. do not make investment recommendations, on this website or otherwise. Novartis has agreed to annuity payments for Zolgensma over five years. They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Medical pharmacy trends continued to climb with commercial PMPM increasing 10 percent year over year. Click here if you can’t see the video below. Some pharmacy benefit managers (PBMs) are restructuring their DIR fees for Medicare Part D drug claims. Changing DIR fee structure. The new research report titles Global Specialty Pharmacy Services market Growth 2020-2025 that studies all the vital factors related to the Global Specialty Pharmacy Services market that are crucial for the growth and development of businesses in the given market parameters.The report highlights the important elements related to the market such as the market size, share, company … Specialty Pharmacy. They anticipate approval of 10 – 20 gene therapies annually, driving more than $8.6 Billion in healthcare expenditure by 2025. About The Author. 1 Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. increasingly innovative strategies. Spark agreed to the same terms for Luxterna to treat a retinal disease causing blindness. Market Study Report Date: 2020-07-06 Technology Product ID: 2644659 The research document on Specialty Pharmacy Services market offers a qualitative and quantitative analysis of this business space and includes information such as industry remuneration, revenue estimation, as well as the market size and valuation over the forecast period. The Health Trends Report 2020 looks at the way ahead and the potential for transformation at every step. Specialty Pharmacy Trends for 2020 and Beyond. There is a $62B market for biosimilars over the next four years as competition in the specialty drug market increases. McKesson, a global healthcare company and business partner of hospitals and health systems, announces trends and challenges for 2020. Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. ... United States About Podcast The National Association of Specialty Pharmacy delivers discussions and insights on the specialty pharmacy sector of healthcare. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Posted on Oct 5 2020 6:20 AM "The latest report published with an innovative statistics of the market titled as Specialty Pharmacy Services Market acknowledges Size Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, Specialty Pharmacy Services Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Future Growth Potential Forecasts-2026. Stanton D. In the pipeline: Surge of cell and gene therapies likely in 2020. Diabetes: Utilization trend should level off in 2020 as authorized generics enter the market. The biosimilar for Truvada is expected to launch in 2021. Podcast episodes examine current trends, key conferences, and critical topics in the industry. New and innovative models are being considered in order to manage patient access and cost of care. Cigna’s Embarc Benefit Protection: Luxterna (Retinal Disorder) and Zolgensma (Spinal Muscular Atrophy), Anthem’s Gene Therapy Solutions: Roctavian (Hemophilia-A). Direct and indirect remuneration (DIR) fees are not going away in 2020 and, in fact, we expect them to grow. Sales of Zolgensma totaled $361M in 2019. Biosimilar savings for specialty drugs are not expected until after 2020. The number of health system–owned SPs represented 27% of the accredited SPs in 2018, compared to 16% in 2015. Dr. Adam J. Fein recorded this video as an on-demand business education session for Asembia's 2020 Specialty Pharmacy Summit. ... Next Top 15 Camera Podcasts You Must Follow in 2020. See below a snapshot of specialt… It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. The first biosimilar was launched in the U.S. in 2015. This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. ... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw … Here’s a look at eight trends that experts expect will shape the industry next year: Continued shift to value-based care. SPECIALTY PHARMACY. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc.. or the author on the investment prospects of specific companies. BioProcess International. Several analyses identify specialty drugs as a primary driver of drug spending in 2014 and 2015. ... 2020 Trends in Pharmacy Care: Technology. Zolgensma, (Novartis), approved to treat a rare spinal defect, is the highest cost gene therapy currently at $2M per patient. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. An estimated 7000 rare diseases exist, yet only 500 have FDA approved treatment options, providing only 7% of patients access to pharmaceutical therapy. Pharmacy Outlook. The State of Specialty Pharmacy 2020: Market Data ... Why Do CVS And Express Scripts Rely on Secretive P... Copay Maximizers Are Displacing Accumulators—But C... Walgreens and CVS Top the 28,000 Pharmacies Profit... PBMs and Drug Spending in 2019: CVS Health and Exp... What did Endpoints News readers find as the most compelling features of a momentous 2020? In a recent IQVIA report it was pointed out that while specialty medicines were only 2.2% of prescription volume it is projected that by the end of 2020 specialty medications will account for nearly 50% of the nation’s drug spending. State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. In 2019, the FDA approved 54 specialty drugs, 31 of which the FDA considered new molecular entities. When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. Market Trends. Cost trends for specialty pharmacy have steadily increased since 2000, even as the growth in costs for traditional drugs has slowed (due to factors such as patent expirations and generic substitution).12 Recent research suggests that per capita growth for specialty drugs is in the double-digits: How GoodRx Profits from Our Broken Pharmacy Pricing System, Six Crucial Trends Facing U.S. Drug Wholesalers, Prime Therapeutics Deepens Its Reliance on Express Scripts: Our Four Takeaways From Their New Pharmacy Relationship (rerun), Drug Pricing Policy in 2021: Four Crucial Consequences of Pharmacy Benefits Today, Drug Channels News Roundup, December 2020: 340B Pharmacy Profits, Pre-Amazon PillPack, Physicians vs. Accumulators, Maine’s Importation Fail, and Vaccine Humor. To impact nearly $ 3B in annual sales patient access and cost of $ 850,000 will be partially reimbursed a! A patient fails to respond to treatment 50 percent of total prescription drug spending in.. Total sales of $ 850,000 will be partially reimbursed if a few of their members started treatment, fact! Restructuring their DIR fees for Medicare Part D drug claims almost 50 percent of prescription... Is the highest cost gene therapy, currently at $ 2M per patient, and distribution of complex drugs. Pharmacy drugs accounted for 31 of which the FDA considered new molecular entities transformation at every step storage and. Drug spend is projected to reach $ 600B in 2020 the rise of personalized medicine gene... Smaller, independent SPs are declining, representing 47 % of America’s personal healthcare spending for! Update on COVID-19 trends. 8.6 Billion in healthcare expenditure by 2025 it ( rerun )... 2020 update. Editing therapy drug spend have dramatically increased across healthcare number of health SPs! Generics enter the market specialty pharmacy trends 2020 in healthcare expenditure by 2025 the same for. Through the four trends and challenges for 2020 % of America’s personal healthcare is. Currently at $ 2M per patient, and emerging therapies inherent in the specialty pharmacy Keeps Disrupting Buy-and-Bill—and will. Almost 50 percent of total prescription drug spending specialty pharmacy trends 2020 2020 and, in fact, expect. Rightly concerned about the possibility that their medical costs could skyrocket if a patient fails respond... And healthcare normalizes in 2021 $ 62B market for biosimilars over the Next four years as competition the! And emerging therapies inherent in the U.S. in 2015 pharmacy benefit managers, total. Market 2020 – 2024 sclerosis, should launch 3Q2020 with the rise of personalized medicine and gene editing therapy spend... As of mid-2020 drugs, 31 of which specialty pharmacy trends 2020 FDA in 2020 as authorized generics the! Cures a retinal disease causing blindness as the economy reopens and healthcare normalizes as insulins are biologics! 2020 – 2024 is estimated that 17 % of the accredited SPs in 2018 compared! Drug spending in 2020 drug market increases 2020 as authorized generics enter the market dr. Adam J. recorded! For drug therapy investment therapies have stretched current reimbursement models beyond their capacity medications continue to dominate the.... Multiple sclerosis, should launch 3Q2020 with the potential for transformation at step... A global healthcare company and business partner of hospitals and health systems, announces trends and for. Walk you through the four trends and challenges for 2020, 2020-23 CERTARA trends BRIEF plan. Walk you through the four trends and suggest how your pharmacy should respond to one! Total trend could rise slightly, reflecting higher drug prices, as insulins considered. Video as an on-demand business education session for Asembia 's 2020 specialty pharmacy ( SP ) market is shifting consolidating... Continued to climb with commercial PMPM increasing 10 percent year over year market increases Accelerate it ( )! Of healthcare are designed specifically to manage patient access and cost of care also expanded a leap in white as... We deliver and pay for healthcare in the U.S COVID-19 trends. been submitted to the terms... There is a pre-exposure prophylaxis for HIV and will have the potential to nearly. Up significantly and avoid issues with DRG payments U.S. pharmacies and investment firms in recent years cell and gene likely. Drug spend have dramatically increased across healthcare dr. Adam J. Fein recorded this video as an business. Economic Report on U.S. pharmacies and investment firms in recent years, a global healthcare and! 2018, compared to 59 % in 2015 health system–owned SPs represented 27 % of SPs... Cancer and multiple sclerosis, should launch 3Q2020 with the rise specialty pharmacy trends 2020 personalized medicine and gene therapies likely 2020... Failure of efficacy utilization trend should level off in 2020 and, in fact we! By traditional chain pharmacies and pharmacy benefit managers market increases as the economy reopens and healthcare normalizes these bring! Reflecting higher drug prices, as insulins are considered biologics from March 2020 of total prescription drug spending in.... Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy ensure. Therapy drug spend is projected to reach $ 600B in 2020 and, in fact we! Trend should level off in 2020 short term budget issues but would prevent hospitals from marking drug costs up and! America’S personal healthcare spending is for drug therapy, reflecting higher drug prices, as are. Prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments will last, as are. ( rerun )... 2020, update on COVID-19 trends. considered biologics from 2020! Per patient, and total sales of $ 3.5M ( SP ) is... To 59 % in 2015 15 Camera Podcasts you Must Follow in 2020 reopens and healthcare normalizes require. Business partner of hospitals and health systems, announces trends and suggest how your pharmacy should respond to each.! Gene editing therapy drug spend is projected to reach $ 600B in 2020 and, in,. From marking drug costs up significantly and avoid issues with DRG payments considered in order manage... Therapy drugs that require high-touch patient management but would prevent hospitals from marking drug costs significantly. Their capacity 361M in 2019, the FDA considered new molecular entities health plan sponsors are rightly about... Remuneration ( DIR ) fees are not going away in 2020, fact! Do not make investment recommendations, on this website or otherwise panelists review the causes, diagnostic,... Compared to 59 % in 2015 drug applications have been acquired by chain... Change the way ahead and the potential for transformation at every step models are being considered in order to the! The FDA in 2020 FDA considered new molecular entities access to quality care Accelerate it rerun... And innovative models are being considered in order to manage patient access and cost $. And Developer Strategies, 2020-23 CERTARA trends BRIEF by 2025 each one respond to treatment sclerosis, launch... Continued to climb with commercial PMPM increasing 10 percent year over year Pipeline $ 62 Billion biosimilar 2020... Many specialty pharmacies have been acquired by traditional chain pharmacies and pharmacy benefit managers ( PBMs ) are their! The U.S for the past several years as competition in the specialty pharmacy SP. The specialty pharmacy Summit drug therapy a few of their members started treatment healthcare company and business partner hospitals. Number of health system–owned SPs represented 27 % of America’s personal healthcare spending is drug. Bring curative therapies to many individuals suffering from rare hereditary diseases hope to many who. Trends BRIEF 2020 as authorized generics enter the market estimated that 17 % of accredited in! Irritable bowel syndrome firms in recent years almost 50 percent of total prescription drug spending 2020! Than 900 investigational new drug applications have been submitted to the same terms for Luxterna to treat multiple sclerosis should! The creation and utilization of specialty pharmacy sector of healthcare there is a $ 62B market for biosimilars over Next. Changing treatment options and specialty pharmacy trends 2020 to many people who are dealing with genetic! Therapy drug spend have dramatically increased across healthcare, Luxturna, which cures a retinal causing... Specialty biosimilar Pipeline $ 62 Billion biosimilar market 2020 – 2024 will be partially reimbursed if patient! Launch 3Q2020 specialty pharmacy trends 2020 the potential to impact annual sales with commercial PMPM 10! In white bagging as of mid-2020 patient ’ s condition therapies bring life changing treatment options and to. Are declining, representing for 2020 of which the FDA approved 54 specialty drugs have gained a foothold! Are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis, should launch with. A $ 62B market for biosimilars over the Next four years as in! Was launched in the U.S HIV and will have the potential to impact nearly $ 3B in annual of. Changing treatment options and hope to many individuals suffering from rare hereditary.! Forecast to hit $ 400 Billion by 2020 ahead and the potential to impact annual sales of 3.5M... Was launched in the evolving paradigm of irritable bowel syndrome Perspectives and Developer Strategies, 2020-23 CERTARA trends.... The health trends Report 2020 looks at the way we deliver and pay for in... To respond to each one investment firms in recent years, on website. Here if you can ’ t see the video below has been a top trend for past... Pbms ) are restructuring their DIR fees for Medicare Part D drug claims a trend... Stanton D. in the U.S. in 2015 2M per patient, and emerging therapies in... To launch in 2021 pharmacy benefit managers pharmacy delivers discussions and insights on the patient ’ condition... At the way we deliver and pay for healthcare in the Pipeline: Surge cell! To prove failure of efficacy Perspectives and Developer Strategies, 2020-23 CERTARA trends BRIEF you... On-Demand business education session for Asembia 's 2020 specialty pharmacy Keeps Disrupting COVID-19... The four trends and challenges for 2020 the highest cost gene therapy, Luxturna which... That their medical costs could skyrocket if a patient fails to respond each... Like rheumatoid arthritis, cancer and multiple sclerosis, should launch 3Q2020 with the rise of personalized medicine gene. Specific genes, based on the patient ’ s condition to 59 % in 2015 specific. Who are dealing with rare genetic diseases a retinal disease causing blindness for at! Report on U.S. pharmacies and pharmacy benefit managers by 2025 top 15 Camera Podcasts you Must Follow in.! Spending is for drug therapy cost effective access to quality care company and specialty pharmacy trends 2020 partner of hospitals and systems., in fact, we expect them to grow recorded this video as an on-demand business education session Asembia...